EP0393782A2 - Catecholamine esters - Google Patents

Catecholamine esters Download PDF

Info

Publication number
EP0393782A2
EP0393782A2 EP90200938A EP90200938A EP0393782A2 EP 0393782 A2 EP0393782 A2 EP 0393782A2 EP 90200938 A EP90200938 A EP 90200938A EP 90200938 A EP90200938 A EP 90200938A EP 0393782 A2 EP0393782 A2 EP 0393782A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
formula
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP90200938A
Other languages
German (de)
French (fr)
Other versions
EP0393782A3 (en
EP0393782B1 (en
Inventor
Cesare Casagrande
Francesco Santangelo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon Group SpA
Original Assignee
SIMES Societa Italiana Medicinali e Sintetici SpA
Zambon Group SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIMES Societa Italiana Medicinali e Sintetici SpA, Zambon Group SpA filed Critical SIMES Societa Italiana Medicinali e Sintetici SpA
Publication of EP0393782A2 publication Critical patent/EP0393782A2/en
Publication of EP0393782A3 publication Critical patent/EP0393782A3/en
Application granted granted Critical
Publication of EP0393782B1 publication Critical patent/EP0393782B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C219/30—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids

Abstract

A compound of formula
Figure imga0001
 (wherein R, R₁ and R₂ have the meanings given in the description),
salts thereof with pharmaceutically acceptable organic or inorganic acids, process and intermediates for the preparation thereof and a pharmaceutical composition containing said compound are described.
The compounds of formula I and the salts thereof are useful in the treatment of heart and renal deases.

Description

  • The present invention relates to dopamine and epinine esters, to salts thereof with pharmaceutically acceptable organic or inorganic acids, to a process and intermediates for the preparation thereof and to pharmaceutical compositions containing them.
  • A first object of the present invention is to provide a compound of formula
    Figure imgb0001
     wherein
    R is hydrogen or methyl;
    R₁ and R₂, different from each other, are a group R₃CO wherein R₃ is
    - a C₁-C₁₀ straight or branched alkyl,
    - a phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkylcarbonyl and halogens, or
    - a group -NR₄R₅ wherein R₄ and R₅, which may be the same or different, are hydrogen, C₁-C₁₀ alkyl or phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkyl­carbonyloxy, C₁-C₃ alkylcarbonyl and halogens, or R₄ and R₅, together, are a polymethylene chain having from 4 to 7 carbon atoms; or,
    one from R₁ and R₂ has the above mentioned meanings and the second one is a group R₄R₅-N-SO₂ wherein R₄ and R₅ have the above mentioned meaning;
    and the salts thereof with organic or inorganic pharmaceutically acceptable acids.
  • The compounds of the present invention are useful in the treatment of cardiovascular and renal deseases.
  • Preferred meanings of R₃ according to this invention are methyl, ethyl, isopropyl, isobutyryl, phenyl and 4-methyl­phenyl.
  • Preferred meanings of R₄ and R₅ are methyl or ethyl.
  • A further object of this invention is to provide a process for the preparation of a compound of formula I and the salts thereof, comprising
    • (i) reducing a compound of formula
      Figure imgb0002
       optionally protected at the amino group, wherein R has the above mentioned meaning, X and X′, together, are an oxygen atom, or X′ is H and X is halogen (bromine or chlorine) or hydroxy, and
    • (ii) removing the protective group, if any, from the amino group to yield a compound of formula I, and
    • (iii) if desired, adding a pharmaceutically acceptable organic or inorganic acid to a compound of formula I to yield the corresponding salt.
  • The process of this invention is accomplished according to conventional techniques. For example, when X and X′, together, are an oxygen atom , step (i) is preferably performed by catalytic hydrogenation or by treatment with hydrides such as triethyl silyl hydride. When X′ is hydrogen and X is halogen, the latter is removed by conventional hydrogenolysis
  • When X and X′, together, are an oxygen atom the preparation of the compound of formula II is preferably carried out from adrenalone (Merck Index 10th Edition, page 26, N° 158) or noradrenalone according to the following scheme.
    Figure imgb0003
     wherein R, R₁ and R₂ have the above mentioned meanings.
  • The compound of formula IV undergoes a first monoesterification at the hydroxy group on position 3 to yield a monoester of formula III.
  • The monoester III is then further esterified at the free hydroxy group on position 4 by treatment with strong bases, such as sodium hydride or sodium or potassium alcoholates.
  • The esterification reactions are performed using reactive derivatives of carboxylic, carbamic or sulfamic acids, in an inert organic solvent at a temperature of from 0°C to the reflux temperature of the reaction mixture.
  • Typical examples of reactive derivatives are carboxylic, carbamic or sulfamic acid halides, preferably chlorides.
  • Suitable solvents are hydrocarbons, halocarbons, ethers, esters, amides, tertiary or heterocyclic amines; specific examples are methylene chloride, dioxane, ethyl acetate, dimethylformamide and pyridine.
  • In turn, when X is halogen or hydroxy and X′ is H, the compound of formula II is preferably prepared according to scheme 2.
    Figure imgb0004
     wherein R, R₁ and R₂ have the above mentioned meanings and X are preferably chlorine or bromine.
  • The compound of formula II (wherein X and X′, together, is an oxygen atom) prepared according to scheme 1, is reduced according to conventional techniques, such as catalytic hydrogenation or reduction with sodium boron hydride or lithium boron hydride, to the corresponding aminoalcohol of formula II (wherein X′ is H and X is OH) that may be then converted into the corresponding haloderivative of formula II (wherein X′ is hydrogen and X is halogen) by treatment with halogenating agents such as, for example, thionyl, chloride and boron tribromide.
  • It will be apparent to the artisan that the process for preparing the compounds of formula I may optionally comprise the protection of the amino group of the starting compounds of formula IV.
  • The protection reaction is carried out according to known techniques, preferably using benzyloxycarbonyl or t.butoxy­carbonyl as protective group.
  • The subsequent removal of the protective group may be performed according to conventional techniques after the esterification reactions to give a compounds of formula II or after the reduction step (i) to give a compound of formula I.
  • Alternatively, both the deprotection of the amino group and the reduction of the carbonyl group of the compound of formula II wherein X and X′, together, are an oxygen atom or the removal of the halogen atom from the compound of formula II wherein X is halogen and X′ is hydrogen may be performed in a single step by catalytic hydrogenation.
  • Step (iii) is carried out according to conventional techniques.
  • Preferably the pharmaceutically acceptable acid is added to the reaction mixture in step (i) or (ii), thus obtaining the desired compound as a salt.
  • Examples of suitable pharmaceutically acceptable acids are hydrochloric, hydrobromic, methanesulfonic, citric and tartaric acid.
  • Some compounds of formula II are novel.
  • It is therefore another object of this invention to provide the compounds of formula
    Figure imgb0005
     wherein
    the asterisk identifies an asymmetric carbon atom,
    R is hydrogen or methyl;
    one from R₁ and R₂
    is a group R₃CO wherein R₃ is a group -NR₄R₅ wherein R₄ and R₅, which may be the same or different, are hydrogen, C₁-C₁₀ alkyl or phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkylcarbonyl and halogens, or R₄ and R₅, together, are a polymethylene chain having from 4 to 7 carbon atoms; and
    the remaining substituent from R₁ and R₂
    is a group R₃CO wherein R₃ is a C₁-C₁₀ straight or branched alkyl, or a phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxylcarbonyl and halogens,
    and the salts thereof with organic or inorganic pharmaceutically acceptable acids.
  • Preferred meanings of R₄ and R₅ in the compounds of formula IIB are hydrogen methyl and ethyl.
  • The compounds of formula IIB have an asymmetric carbon atom and may therefore be in form of single stereoisomers or of a racemic mixture. All these forms are an object of this invention. Their preparation may be accomplished by conventional techniques such as separation from the racemic mixture by crystallization or chromathography. Alternatively, the desired stereoisomer may be prepared by stereoselective reduction with chiral hydrides, chiral catalysts or biotechnological processes.
  • A further object of this invention is to provide a process for the preparation of a compound of formula (IIB) comprising
    • (i) reducing a compound of formula
      Figure imgb0006
       wherein
      R, R1 and R2 have the meanings mentioned in relation to formula IIB,
      with a suitable reducing agent to afford a compound of formula IIB,
    • (ii) optionally resolving the racemic mixture, if any, and
    • (iii) if desired, adding an organic or inorganic acid to a compound of formula IIB to yield the corresponding salt.
  • The above process may be carried out according to conventional techniques. Step (i) is preferably accoplished by catalytic hydrogenation, or with a suitable reducing agent such as sodium or lithium boron hydride.
  • The compounds of formula I are useful in therapy in the treatment of heart failure, renal failure, hypertension, pathological syndromes characterized by water or salts retention or pathological syndromes characteristic of the insufficient perfusion of vital organs.
  • The compounds of the present invention exert a vasodilating action on the renal district and a positive inotropic effect, producing a dose-depending increase of dP/dt (i.e. derivative of left ventricle pressure) at a dose of 1-100 mg/kg i.p., in the anesthetized dog.
  • Mongrels of both sexes anesthetized with sodium pento­barbital (35 mg/kg e.v.) were used. Artificial respiration was accomplished by means of an endotracheal tube with a Starling Ideal pump at a ventilation frequency of 16-18 cycles/minute, a flow rate of 16-17 ml/kg in order to obtain pO₂, pCO₂ and pH values of arterial blood of 85-100 mmHg, 30-40 mmHg and 7.35-7.45, respectively (Radiometer Copenhagen BMS 3MK 2 Blood Microsystem Blood Gas Analyzer). Duodenum was insulated by abdomen incision and a polyethylene catheter was inserted for administering the medicament. Left renal artery was isolated retroperitoneally; an electromagnetic transducer and a pneumatic obturator were positioned around the vessel to measure the blood flow and the mechanical zero, respectively.
  • Myocardium contractility was evalueted as the first derivative LVdP/dt of the left ventricle pressure (LVP) measured by means of a polyethylene catheter inserted into the left ventricle through the left carotid artery.
  • Emodynamic parameters were recorded on a Gould Brush MK 200 Graph Recorder while the pressure catheters were connected to a Bell and Howell Pressure Transducers and the electromagnetic flow transducer was connected to a Biotronex BL 613 Flowmeter.
  • The compounds of formula I are endowed with a greater bioavailability and a longer lasting action than dopamine and epinine and can thus be administered also orally.
  • Therefore, it is a further object of the present invention to provide a pharmaceutical composition containing a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, together with one or more excipients suitable for pharmaceutical use. The pharmaceutical compositions of the present invention may be formulated as solid preparations, such as tablets, pills, capsules, powders, pellets and suppositories, or as liquid preparations, such as suspensions, emulsions and solutions possibly to be prepared just before their use, or semi-solid preparations, such as creams, ointments and liniments.
  • They may also be formulated as pharmaceutical forms having a controlled or delayed release. All these formulations are prepared in conventional ways.
  • Moreover, in the formulations may be incorporated other compatible active ingredients which have a complementary therapeutical action.
  • Furthermore, it has been found that the compounds of formula IIB are useful in the ophthalmological field in conjunctival hyperemia, in controlling local hemorrhages, in the regulation of ocular pressure in glaucoma and in patients suffering from ocular hyperpression, and as a mydriatic.
  • It is therefore a further object of this invention to provide a composition for use in ophthalmogy that contains a therapeutically or diagnostically effective amount of a compound of formula IIB or a pharmaceutically acceptable acid addition salt thereof, together with one or more pharmaceutical exipients.
  • Said compositions are preferably liquid, such as solutions, or semiliquid, such as creams. A solution according to this invention will preferably contain from 0.01% to 1% of a compound of formula IIB or the equivalent amount of an acid addition salt thereof. The daily dosage will vary depending on selected use and the individual response of the patient but usually it will be in the range from 0.1 to 1 mg in one or repeated administrations.
  • The following examples are now provided in order to better disclose the present invention.
    • Example 1
  • To a suspension of NaH 60% in mineral oil (1.53 g) in anhydrous dimethylformamide (50 ml), at 0°C and under a nitrogen atmosphere, is added a solution of alfa-(N-benzyloxy­carbonyl-N-methylamino)-3,4-dihydroxyacetophenone (20 g) in dimethylformamide (50 ml).
  • After 15 minutes p.toluylchloride (8.5 ml) is added always at 0°C.
  • After 24 hrs at room temperature the solution is neutralized with acetic acid and evaporated to dryness. The residue is added with water, acidified with acetic acid and extracted with methylene chloride. The organic phase is dried over sodium sulphate and the solvent is evaporated.
  • The crude product is purified by silica gel column chromatography (eluent, methylene chloride) yielding alfa-(N-­benzyloxycarbonyl-N-methylamino)-3-(4-methylbenzoyloxy)-4-­hydroxyacetophenone.
    m.p. 128-134°C (from ethyl acetate/ethyl ether)
  • Working in a similar manner, the following compounds were prepared:
    alfa-(N-benzyloxycarbonyl-N-methylamine)-3-isobutirryloxy-4-­hydroxyacetophenone
    m.p. 138-140 °C (ethyl ether)
    alfa-benzyloxycarbonylamino-3-(4-methylbenzoyloxy)-4-hydroxy­acetophenone
    m.p. 172-175 °C (ethyl acetate)
    • Example 2
  • To a solution of alfa-(N-benzyloxycarbonyl-N-methylamino)-3-­(4 -methylbenzoyloxy)-4-hydroxyacetophenone (20 g; 46 mmoli), prepared as described in example 1, in anhydrous dimethyl­ formamide (200 ml) a suspension of NaH 60% in mineral oil (1.32 g) at 0°C and under a nitrogen atmosphere is added.
  • After two hours at 0°C, a solution of isobutyrylchloride (5.9 g; 55 mmoles) in anhydrous dimethylformamide (10 ml).After one hour, the reaction mixture is poured in iced water and repeatedly extracted with ether.
  • The organic extracts are combined and dried over sodium sulphate and evaporated thus yielding alfa-(N-benzyloxy­carbonyl-N-methylamino)-3-(4-methylbenzoyloxy)-4-isobutyryloxy-­acetophenone as an oil (thin layer chromatography: eluent, toluene:ethyl acetate = 8:2; detection U.V., I₂ vapors).
    ¹H-NMR (60 MHz, CDCl₃): delta (ppm): 1.10 (6H, d); 2.45 (3H, s); 2.68 (1H, m); 3.02 (3H, s); 4.70 (2H, d); 5.20 (2H, d); 7.21-8.10 (12H, m).
  • Working in a similar manner, the following compounds were prepared:
    alfa-(N-benzyloxycarbonyl-N-methylamino)-3-(4-methylbenzoyloxy)­-4-(N,N-dimethylcarbamoyloxy)acetophenone
    oil, (thin layer chromatography: eluent, CH₂Cl₂:toluene:CH₃OH = 25:5:3; detection U.V., I₂ vapors).
    ¹H-NMR (60MHz, CDCl₃): delta (ppm): 2.46 (3H, s); 2.88 (6H, s); 3.06 (3H, s); 4.73 (2H, d); 5.20 (2H, d); 7.30-8.23 (12H, m).
    alfa-(N-benzyloxycarbonyl-N-methylamino)-3-isobutyryloxy-4-(4-­methylbenzoyloxy)acetophenone
    m.p. 102-104 °C (ethyl ether/petroleum ether).
    alfa-benzyloxycarbonylamino-3-(4-methylbenzoyloxy)-4-(N,N-­dimethylcarbamoyloxy)acetophenone
    m.p. 147-148°C (ethyl ether).
    alfa-benzyloxycarbonylamino-3-(4-methylbenzoyloxy)-4-(iso­butyrloxy)acetophenone
    oil ( thin layer chromatography: eluent, CH₂Cl₂:ethyl acetate = 9:1; detection U.V. light, I₂ vapors)
    ¹H-NMR (60 MHz, CDCl₃):delta (ppm): 1.15 (6H, d); 2.46 (3H, s); 4.71 (2H, d); 5.25 (2H, s); 7.20-8.23 (12H, m).
    alfa-(N-benzyloxycarbonyl-N-methylamino)-3-isobutyryloxy-4-(N-m­ethylcarbamoyloxy)acetophenone
    oil; in this case, it has not been necessary to use NaH as a base (thin layer chromatography: eluent, toluene : ethyl acetate 8 : 2, or CH₂Cl₂:toluene:CH₃OH = 25:5:3; detection U.V., I₂ vapors).
    Mass spectrum (chemical ionization, positive ions, ionization gas : isobutane) m/e 443 (M⁺ +1).
    alfa-(N-benzyloxycarbonyl-N-methylamino)-3-isobutyryloxy-4-(N,N-­dimethylsulfamoyloxy)acetophenone
    oil, (thin layer chromatography: eluent, CH₂Cl₂: CH₃OH = 98 : 2; detection U.V., I₂ vapors).
    Mass spectrum (chemical ionization, positive ions, ionization gas : ammonia) m/e 493 (M⁺ +1).
    alfa-(N-benzyloxycarbonyl-N-methylamino)-3-isobutyryloxy-4-(4-m­ethoxycarbonylbenzoyloxy)acetophenone
    m.p. 88-89°C (ethyl ether/ petroleum ether).
    alfa-(N-benzyloxycarbonyl-N-methylamino)-3-isobutylryloxy-4-(4-i­sobutyryloxybenzoyl)acetophenone
    oil, (thin layer chromatography: eluent, toluene : ethyl acetate = 7 : 3; detection U.V., I₂ vapors).
    Mass spectrum (chemical ionization, positive ions, ionization gas : ammonia) m/e 473 (M⁺ +18), 456 M⁺ +1).
    • Example 3
  • To a solution of alfa-(N-benzyloxycarbonyl-N-methylamino)-­3-(4-methylbenzoyloxy)-4-isobutyryloxy-cetophenone (23.2 g; 46.87 mmoles), prepared as described in example 2, in methanol (230 ml) at 0-5°C, sodium boron hydride (1.74 g; 45.99 mmoles) is added.
  • After 45 minutes the solution is acidified with hydrochloric acid, concentrated to small volume, diluted with methylene chloride and washed with water.
  • After drying over sodium sulphate, the solvent is evaporated yielding 3-O-(4-methylbenzoyl)-4-O-isobutyryl-N-benzyloxy­carbonyladrenaline as an oil (thin layer chromatography; eluent, toluene:ethyl acetate = 7:3; detection U.V. light, I₂ vapors)
    ¹H-NMR (60 MHz, CDCL₃): delta (ppm): 1.06 (6H, d); 2.40 (3H, s); 2.63 (1H, m); 2.83 (3H, s); 3.50 (2H, d); 4.91 (1H, t); 5.08 (2H, s); 7.16-7.33 (10H, m); 8.06 (2H, d).
  • Working in a similar manner, the following compounds were prepared: 3-O-(4-methylbenzoyl)-4-O-(N,N-dimethylcarbamoyl)-N-benzyloxy­carbonyladrenaline
    oil (thin layer chromatography; eluent, toluene: ethyl acetate = 1:1; detection U.V. light,I₂ vapors)
    ¹H-NMR (60 MHz, CDCl₃): delta (ppm): 2.48 (3H, s); 2.86 (6H, s); 2.95 (3H, s); 3.53 (2H, d); 5.03 (1H, m); 5.23 (2H, s); 7.25-7.40 (10H, m); 8.06 (2H, d).
    3-O-isobutyryl-4-O-(4-methylbenzoyl)-N-benzyloxycarbonyladrena­line
    oil (thin layer chromatography; eluent, toluene : ethyl acetate = 7:3; detection U.V.light, I₂ vapors)
    ¹H-NMR (60 MHz, CDCl₃): delta (ppm): 1.10 (3H, d); 2.56 (3H, s); 2.66 (1H, m); 2.98 (3H, s); 3.50 (2H, d); 5.00 (1H, m); 5.18 (2H, s); 7.23-7.36 (10H, m); 8.08 (2H, d).
    3-O-(4-methylbenzoyl)-4-O-isobutyryl-N-benzyloxycarbonylnoradre­naline
    oil (thin layer chromatography; eluent CH₂Cl₂: ethyl acetate = 9:1; detection U.V.light, I₂ vapors)
    ¹H-NMR (60 MHz, CDCl₃): delta (ppm): 1.10 (6H, d); 2.43 (3H, s); 2.70 (1H, m); 3.40 (2H, m); 4.85 (1H, m); 5.13 (2H, s); 7.18-7.38 (10H, m); 8.13 (2H, m).
    3-O-(4-methylbenzoyl)-4-O-(N,N-dimethylcarbamoyl)-N-benzyloxy­carbonylnoradrenaline
    oil (thin layer chromatography, eluent, toluene:methanol = 95 : 5; detection U.V. light, I₂ vapors)
    ¹H-NMR (60 MHz, CDCl₃): delta (ppm): 2.41 (3H, s); 2.85 (6H, s); 3.39 (2H, d); 4.78 (1H, m); 5.16 (2H, s); 7.26-7.43 (10H, m); 8.16 (2H, d).
    3-O-isobutyryl-4-O-(4-methylcarbamoyl)-N-benzyloxycarbonyladre­aline
    oil (thin layer chromatography; eluent, CH₂Cl₂: toluene : CH₃OH = 25 : 5 : 4; detection U.V. light, I₂ vapors)
    Mass spectrum (chemical ionization, positive ions, ionization gas : isobutane) m/e 445 (M⁺ +1).
    3-O-isobutyryl-4-O-(N,N-dimethylsulfamoyl)-N-benzyloxycarbonyla­drenaline
    oil (thin layer chromatography; eluent, CH₂Cl₂: toluene : CH₃OH = 25 : 5 : 2; detection U.V. light, I₂ vapors)
    Mass spectrum (chemical ionization, positive ions, ionization gas : ammonia) m/e 495 (M⁺ +1).
    3-O-isobutyryl-4-O-(4-methoxycarbonylbenzoyl)-N-benzyloxycarbon­yladrenaline
    oil (thin layer chromatography; eluent, CH₂Cl₂: toluene : CH₃OH = 25 : 5 : 2; detection U.V. light, I₂ vapors)
    Mass spectrum (chemical ionization, positive ions, ionization gas : ammonia) m/e 550 (M⁺ +1).
    3-O-isobutyryl-4-O-(4-isobutyryloxybenzoyl)-N-benzyloxycarbonyl­adrenaline
    oil (thin layer chromatography; eluent, CH₂Cl₂: toluene : CH₃OH = 25 : 5 : 3; detection U.V. light, I₂ vapors)
    Mass spectrum (chemical ionization, positive ions, ionization gas : ammonia) m/e 578 (M⁺ +1).
    • Example 4
  • 10% palladium on charcoal (2.4 g) was added to a solution of 3-O-(4-methylbenzoyl)-4-O-isobutyryl-N-benzyloxycarbonyladre­naline (12 g; 23.74 mmoles), prepared as described in example 3, in acetic acid (100 ml) and HCl 37% in ethanol (3.5 ml).
  • The suspension is hydrogenated at room temperature at a hydrogen pressure of 2-3 atmospheres. After theoretical adsorption of hydrogen, the suspension is filtered and evaporated.
  • The oily residue is crystallized from ethyl ether yielding 3-O-(4-methylbenzoyl)-4-O-isobutyryl adrenaline hydrochloride, with m.p. 147-149°C.
  • Working in a similar manner, the following compounds were obtained:
    3-O-(4-methylbenzoyl)-4-O-(N,N-dimethylcarbamoyl)adrenaline hydrochloride
    chromatographically pure hygroscopic solid (thin layer chromatography; eluent, CH₂Cl₂:CH₃OH:CH₃COOH = 79:15:1, detection I₂ vapors).
    ¹H-NMR (60MHz, CDCl₃): delta (ppm): 2.30 (3H, s); 2.66 (9H, s); 3.08 (2H, m); 5.08 (1H, m); 7.02-7.48 (5H, m); 7.90 (2H, d).
    3-O-isobutyryl-4-O-(N,N-dimethylcarbamoyl)adrenaline hydrochloride
    chromatographically pure hygroscopic solid (thin layer chromatography; eluent, CH₂Cl₂:CH₃O H:H₂O:CH₃COOH = 79:15:1:1, detection I₂ vapors).
    ¹H-NMR (300MHz, D₂O): delta (ppm): 1.27 (6H, d); 2.77 (3H, s); 2.92 (1H, sextet); 2.96 (3H, s); 3.08 (3H, s); 3.24-3.38 (2H, m); 5.08-5.13 (1H, 2d); 7.30-7.42 (3H, m).
    3-O-isobutyryl-4-O-(4-methylbenzoyl)adrenaline hydrochloride
    m.p. 141-144°C (from ethyl ether)
    3-O-(4-methylbenzoyl)-4-O-isobutyryl-noradrenaline hydrochloride
    chromatographically pure oil (thin layer chromatography, eluent CH₂Cl₂:CH₃OH:CH₃COOH= 79:15:1; detection I₂ vapors).
    ¹H-NMR (60 MHz, DMSO-d₆): delta (ppm); 1.06 (6H, d); 2.46 (3H, s); 3.13 (2H, m); 5.08 (1H, m); 7.38-7.56 (5H, m); 8.13 (2H, m).
    3-O-(4-methylbenzoyl)-4-O-(N,N-dimethylcarbonyl)-noradrenaline hydrochloride
    chromatographically pure oil (thin layer chromatography, eluent CH₂Cl₂:CH₃OH:CH₃COOH = 79:15:1; detection I₂ vapors).
    ¹H-NMR (60 MHz, DMSO-d₆): delta (ppm): 2.48 (3H, s); 2.82 (6H, s); 3.02 (2H, m); 5.06 (1H, m); 7.28-8.20 (7H, m).
    3-O-isobutyryl-4-O-(4-methylcarbamoyl)adrenaline hydrochloride
    oil (thin layer chromathography; eluent, methylene chloride : methyl alcohol : water : acetic acid = 79 : 15 : 1 : 1; detection I₂ vapours)
    Mass spectrum (chemical ionization, positive ions, ionization gas : isobutane) m/e 311 (M⁺ + 1)
    ¹H-NMR (300 MHz, D₂O) delta (ppm): 1.28 (6H, d), 2.76 (6H, s), 2.9 (1H, m), 3.24-3.38 (2H, m), 5.01 (1H, dd), 7.30-7.42 (3H, m).
    3-O-isobutyryl-4-O-(N,N-dimethylsulfamoyl)-adrenaline hydrochloride
    m.p. 155-157°C (ethyl alcohol)
    3-O-isobutyryl-4-O-(4-methoxycarbonylbenzoyl)-adrenaline hydrochloride
    m.p. 167-171°C (ethyl acetate)
    3-O-isobutyryl-4-O-(4-isobutyryloxybenzoyl)-adrenaline hydrochloride
    m.p. 145-150°C (methylene chloride/ethyl ether)
    • Example 5
  • Thionyl chloride (4.66 g; 39.17 mmoles) is added to a solution of 3-O-(4-methylbenzoyl)-4-O-isobutyryladrenaline hydrochloride (4 g; 7.38 mmoles), prepared as described in example 4, in anhydrous methylene chloride (40 ml), kept at 0°C under nitrogen atmosphere.
  • After one hour at room temperature the solution is evaporated. The residue is crystallized from ethyl ether/ethyl acetate yielding 2-chloro-2-/3-(4-methylbenzoyloxy)-4-iso­butyryloxyphenyl/-N-methyl-ethylamine hydrochloride, m.p. 182-184°C.
  • Working in a similar manner, the following compounds are obtained:
    2-chloro-2-/3-(4-methylbenzoyloxy)-4-(N,N-dimethylcarbamoyloxy)-­phenyl/-N-methyl-ethylamine hydrochloride
    m.p. 170-173°C (ethyl acetate/ethyl ether)
    2-chloro-2-/3-isobutyryloxy-4-(4-methylbenzoyloxy)-phenyl/-N-­methyl-ethylamine hydrochloride
    m.p. 172-175°C (ethyl ether)
    2-chloro-2-/3-(4-methylbenzoyloxy)-4-isobutyryloxy-phenyl/ethyl­ amine hydrochloride
    chromatographically pure oil (thin layer chromatography; eluent, CH₂Cl₂:CH₃OH;CH₃COOH = 79:15:1; detection, I₂ vapors).
    ¹H-NMR (60 MHz, DMSO-d₆): delta (ppm): 1.05 (6H, d); 2.50 (3H, s); 3.56 (2H,m); 5.68 (1H, m); 7.33-8.15 (7H, m).
    2-chloro-2-/3-(4-methylbenzoyloxy)-4-(N,N-dimethylcarbamoyloxy)-­phenyl/ethylamine hydrochloride
    chromatographically pure oil (thin layer chromatography; eluent, CH₂Cl₂:CH₃OH:CH₃COOH = 79:15:1; detection, U.V.light, I₂ vapours).
    ¹H-NMR (60 MHz, DMSO-d₆): delta (ppm): 2.46 (3H, s); 2.84 (6H, s); 3.56 (2H, d); 5.66 (1H, t); 7.40-8.30 (7H, m).
    2-chloro-2-/3-isobutyryloxy-4-(N-methylcarbamoyloxy)-phenyl/­ethylamine hydrochloride
    m.p. 138-139°C (ethyl acetate)
    2-chloro-2-/3-isobutyryloxy-4-(N,N-dimethylsulfamoyloxy)-phenyl/­-ethylamine hydrochloride
    m.p. 156-158°C (ethyl ether)
    2-chloro-2-/3-isobutyryloxy-4-(4-methoxycarbonylbenzoyloxy/-­phenyl/-ethylamine hydrochloride
    m.p. 145-166°C (slow decomposition, toluene/ethyl ether)
    2-chloro-2-/3-isobutyryloxy-4-(4-isobutyryloxybenzoyloxy)phenyl/­-ethylamine hydrochloride
    • Example 6
  • 10% palladium on charcoal (1 g) is added to a solution of 2-chloro-2-/3-(4-methylbenzoyloxy)-4-isobutyryloxyphenyl/-N-met­hyl-ethylamine hydrochloride (3.5 g; 6.67 mmoles), prepared as described in example 5, in anhydrous dimethylformamide (35 ml).
  • The suspension is hydrogenated at room temperature at a hydrogen pressure of 2-3 atmospheres. After theoretical adsorption of hydrogen, the suspension is filtered and evaporated.
  • The residue is crystallized from ethanol/ethyl ether yielding 3-O-(4-methylbenzoyl)-4-O-isobutyryl-N-methyl-dopamine hydrochloride, m.p. 140-141°C.
  • Working in a similar manner, the following compounds were prepared:
    3-O-(4-methylbenzoyl)-4-O-(N,N-dimethylcarbamoyl)-N-methyl-dopa­mine hydrochloride
    m.p. 112-114°C (ethyl acetate)
    3-O-isobutyryl-4-O-(4-methylbenzoyl)-N-methyl-dopamine hydro­chloride
    m.p. 193-194°C (ethanol/ethyl ether)
    bis/3-O-(4-methylbenzoyl)-4-O-isobutyryldopamine/dibudinate
    m.p. 253-254°C (ethanol/ethyl ether)
    bis/3-O-(4-methylbenzoyl)-4-O-(N,N-dimethylcarbamoyl)dopamine/­dibudinate
    m.p. 259-261°C (ethyl alcohol/ethyl ether).
    3-O-isobutyryl-4-O-(N-methylcarbamoyl)-N-methyl-dopamine hydrochloride
    m.p. 192-195°C (ethyl alcohol/ethyl ether)
    ¹H-NMR (300 MHz D₂O) delta (ppm) 1.27 (6H, d), 2.71 (3H, s), 2.78 (3H, s), 2.90 (1H, m), 3.05 (2H, t), 3.32 (2H, t), 7.13-7.29 (3H, m).
    3-O-isobutyryl-4-O-(N,N-dimethylsulfamoyl)-N-methyl-dopamine hydrochloride
    m.p. 143-145°C (ethyl alcohol/ethyl ether)
    ¹H-NMR (300 MHz, D₂O) delta (ppm) 1.31 (6H, d), 2.72 (3H, s), 2.97 (1H, quintetto), 2.39 (6H, s), 3.06 (2H, t), 3.32 (2H, t), 7.24 (1H, d), 7.32 (1H, dd), 7.48 (1H, d)
    3-O-isobutyryl-4-O-(4-methoxycarbonylbenzoyl)-N-methyl-dopamine hydrochloride
    m.p. 208-211°C (ethyl acetate)
    ¹H-NMR (300 MHz, CDCl₃) delta (ppm) 1.09 (6H, d), 2.65 (1H, quintetto), 2.74 (3H, s), 3.19-3.23 (4H, m), 33.95 (3H, s), 7.16-7.24 (3H, m), 8.12-8.21 (4H, m)
    3-O-isobutyryl-4-O-(4-isobutyryloxybenzoyl)-N-methyl-dopamine hydrochloride
    m.p. 167-170°C (methylene chloride/ethyl ether)
    ¹H-NMR (300 MHz, CDCl₃) delta (ppm) 1.00 (6H, d), 1.33 (6H, d), 2.65 (1H, quintetto), 2.82 (1H, quintetto), 3.22 (4H, bs), 7.15-7.21 (5H, m) 8.15 (2H, d).
    • Example 7 Permeability rate of 3-O-(4-methylbenzoyl)-4-O-(N,N-dimethyl­carbamoyl)adrenaline hydrochloride (identified as 2B223) and 3-O-isobutyryl-4-O-(N,N-dimethylcarbamoyl)adrenaline hydrochlo­ride (identified as 2B852). Perfusion method:
  • pig corneas have been removed with about 2 mm of sclera and set on a perfusion cell.
  • The receving compartment and that of the donor were respectively filled with 6 ml and 1 ml of GBR solution (Glutathione Bicarbonate Ringer's solution) preheated at 35°C.
  • During the analysis the cells were maintained at a temperature of 34-35°C with a thermostat (REACTI-THERM, Pierce). Besides, the solutions in the 2 compartments were maintained under a flow of 95% O₂ - 5% CO₂ mixture.
  • The GBR solution in the donor compartment was then substituted with 1 ml of GBR solution saturated with O₂-CO₂ containing, 2B223 or 2B852 (2.5 mM).
  • Aliquots of 600 ul were withdrawn from the receiving compartment every 40 minutes for a period of 4 hours and immediately replaced with an equal volume of GBR.
  • As control acted a solution of GBR with diclofenac (0.1%) maintained at the same conditions (temperature 34-35°C and gassed with (O₂-CO₂), from which were withdrawn aliquots at the same times.
  • The samples and the controls at various times were immediately analyzed by HPLC.
    • Solutions:
  • Glutathione Bicarbonate Ringer's (GBR), pH 7.65. The GBR solution was prepared in two parts: part I was composed of sodium chloride 12.4 g/l, potassium chloride 0.716 g/l, sodium dihydrogen phosphate monohydrate 0.206 g/l and sodium bicarbon­ate 4.908 g/l while part II was composed of calcium chloride 0.230 g/l, magnesium chloride 0.318 g/l, glucose 1.8 g/l and oxidized glutathioine 0.184 g/l. Both parts were stored cold and utilized within two weeks.
  • Equal volumes of part I and II were mixed prior to use. Table 1
    Permeability rate of 2B223 and 2B852 across excissed pig cornea. Amounts (nMoles) of the unchanged product and of epinephrine released by 2B223 and 2B852 in the receiving compartment.
    COMPOUND INITIAL AMOUNT IN DONOR COMPARTMENT (nMoles) PERMEABILITY RATE (nMoles)
    40 min. 80 min. 120 min. 160 min.
    2B223 2450 0.0 1.3 4.1 23.5
    EPINEPHRINE 15.8 21.7 23.4 26.2
    2B852 2770 0.0 0.0 0.0 0.0
    EPINEPHRINE 14.5 23.7 28.9 32.0
  • It is known that epinephrine is a drug potentially useful in ophthalmology; however, it does not permeate cornea barrier when applied topically to the eye. The above experiment shows that epinephrine is released inside the eye after topical administratio of 2B223 and 2B852.
    • Example 8
  • Intraocular pressure in rabbit was also tested as shown in Table 2 and 3. Table 2
    Intraocular pressure (mm Hg) in rabbit after topical application of 0.1% solution of 2B223.
    TIME (hours)
    ANIMAL 0 1 2 4 8
    animal 1 16 12 13 14 15
    animal 2 16 13 14 15 16
    animal 3 15 12 13 14 15
    animal 4 16 11 13 13 14
    animal 5 17 13 14 15 16
    animal 6 16 12 13 14 15
    N 6 6 6 6 6
    MEAN 16.0 12.2 13.3 14.2 15.2
    SD 0.6 0.8 0.5 0.8 0.8
    Table 3
    Intraocular pressure (mm Hg) in rabbit after topical applications of 0.1% solution of 2B852.
    TIME (hours)
    ANIMAL 0 1 2 4 8
    animal 1 15 12 13 14 16
    animal 2 16 13 14 15 15
    animal 3 16 12 14 14 16
    animal 4 16 11 13 14 16
    animal 5 15 11 13 14 14
    animal 6 16 12 14 15 15
    N 6 6 6 6 6
    MEAN 15.7 11.8 13.5 14.3 15.3
    SD 0.5 0.8 0.6 0.5 0.8
    • Example 8 Action of 2B223 and 2B852 on ocular hypertension in man.
  • 1 drop of a 0.1% solution of 2B223 or 2B852, respectively, has been instilled into each eye of 8 patients (males) suffering from non-severe ocular hypertension. Ocular pressure has been tested at time 0, and 30, 120, 180 after the ocular instillation. At same times blood pressure and hearth rate were also tested.
  • The results shown in Table 4 and 5 demostrate that the maximum action is reached after 120 minutes with both compounds.
  • No modification in the blood pressure and heart rate has been found. Both compounds were well tolerated locally. Table 4
    Ocular Pressure (mmHg) after instillation of a drop of a 0.1% solution of 2B223 in right (r.) and left (l.) eye of 4 patients.
    TIME (minutes)
    PATIENT 0 30 120 180
    r. l. r. l. r. l. r. l.
    Patient 1 27 26 24 25 22 20 23 22
    Patient 2 24 26 23 25 21 22 22 24
    Patient 3 23 26 24 25 23 22 24 24
    Patient 4 27 25 25 23 23 22 24 25
    N 4 4 4 4 4 4 4 4
    MEAN 25.3 25.8 24.0 24.5 22.3 21.5 23.3 23.8
    SD 2.1 0.5 0.8 1.0 1.0 1.0 1.0 1.3
    Table 5
    Ocular Pressure (mmHg) after instillation of a drop of a 0.1% solution of 2B852 in right (r.) and left (l.) eye of 4 patients.
    TIME (minutes)
    PATIENT 0 30 120 180
    r. l. r. l. r. l. r. l.
    Patient 1 26 27 25 26 23 24 25 23
    Patient 2 25 26 24 24 22 22 22 23
    Patient 3 24 26 23 25 23 24 23 23
    Patient 4 28 27 26 26 24 25 24 25
    N 4 4 4 4 4 4 4 4
    MEAN 25.8 26.5 24.0 25.3 23.0 23.8 23.5 23.8
    SD 1.7 0.6 0.8 1.0 0.8 1.3 1.3 1.0

Claims (14)

1. A compound of formula
Figure imgb0007
 wherein
R is hydrogen or methyl;
R₁ and R₂, different from each other, are a group R₃CO wherein R₃ is
- a C₁-C₁₀ straight or branched alkyl,
- a phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkyl­carbonyl and halogens, or
- a group -NR₄R₅ wherein R₄ and R₅, which may be the same or different, are hydrogen, C₁-C₁₀ alkyl or phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkyl­carbonyl and halogens, or R₄ and R₅, together, are a polymethylene chain having from 4 to 7 carbon atoms;
or,one from R₁ and R₂ has the above mentioned meanings and the second one is a group R₄R₅-N-SO₂ wherein R₄ and R₅ have the above mentioned meaning;
and the salts thereof with organic or inorganic pharmaceutically acceptable acids.
2. A compound according to claim 1, wherein R₃ is methyl, ethyl, isopropyl, isobutyryl, phenyl or 4-methylphenyl.
3. A compound according to claim 1, wherein R4 and R5 are methyl or ethyl.
4. A pharmaceutical composition containing a therapeutically effective amount of a compound according to claims 1-3, together with one or more pharmaceuticlly acceptable excipients.
5. A process for preparing a compound of formula
Figure imgb0008
 wherein
R is hydrogen or methyl;
R₁ and R₂, different from each other, are a group R₃CO wherein R₃ is
- a C₁-C₁₀ straight or branched alkyl,
- a phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkyl­carbonyl and halogens, or
- a group -NR₄R₅ wherein R₄ and R₅, which may be the same or different, are hydrogen, C₁-C₁₀ alkyl or phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkyl­carbonyl and halogens, or R₄ and R₅, together, are a polymethylene chain having from 4 to 7 carbon atoms;
or,one from R₁ and R₂ has the above mentioned meanings and the second one is a group R₄R₅-N-SO₂ wherein R₄ and R₅ have the above mentioned meaning;
and the salts thereof with organic or inorganic pharmaceutically acceptable acids,
comprising
(i) reducing a compound of formula
Figure imgb0009
 optionally protected at the amino group,
wherein R has the above mentioned meaning,
X and X′, together, are an oxygen atom, or X′ is H and X is halogen or hydroxy, and
(ii) removing the protective group, if any, from the amino group to yield a compound of formula I, and
(iii) if desired, adding a pharmaceutically acceptable organic or inorganic acid to a compound of formula I to yield the corresponding salt.
6. A process according to claim 5, wherein, when X and X′, together, are an oxygen atom, step (i) is performed by catalytic hydrogenation or by treatment with hydrides.
7. A process according to claim 6, wherein step (i) is performed with triethyl silyl hydride.
8. A process according to claim 5, wherein, when X′ is hydrogen and X halogen, step (i) is performed by hydrogenolysis.
9. A process according to claim 8, wherein X is chlorine or bromine.
10. A compound of formula
Figure imgb0010
 wherein
the asterisk identifies an asymmetric carbon atom,
R is hydrogen or methyl;
one from R₁ and R₂
is a group R₃CO wherein R₃ is a group -NR₄R₅ wherein R₄ and R₅, which may be the same or different, are hydrogen, C₁-C₁₀ alkyl or phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkylcarbonyl and halogens, or R₄ and R₅, together, are a polymethylene chain having from 4 to 7 carbon atoms; and
the remaining substituent from R₁ and R₂
is a group R₃CO wherein R₃ is a C₁-C₁₀ straight or branched alkyl, or a phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxylcarbonyl and halogens,
and the salts thereof with organic or inorganic pharmaceutically acceptable acids.
11. A compound according to claim 10, wherein R₄ and R₅ are hydrogen, methyl or ethyl.
12. A process for preparing a compound of formula
Figure imgb0011
 wherein
the asterisk identifies an asymmetric carbon atom,
R is hydrogen or methyl;
one from R₁ and R₂
is a group R₃CO wherein R is a group -NR₄R₅ wherein R₄ and R₅, which may be the same or different, are hydrogen, C₁-C₁₀ alkyl or phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkyl­carbonyloxy, C₁-C₃ alkylcarbonyl and halogens, or R₄ and R₅, together, are a polymethylene chain having from 4 to 7 carbon atoms; and
the remaining substituent from R₁ and R₂
is a group R₃CO wherein R₃ is a C₁-C₁₀ straight or branched alkyl, or a phenyl optionally substituted by one or two substituents selected from C₁-C₃ alkyl, C₁-C₃ alkoxy; C₁-C₃ alkoxylcarbonyl and halogens,
and the salts thereof with organic or inorganic pharmaceutically acceptable acids,
comprising
(i) reducing a compound of formula
Figure imgb0012
 wherein
R, R1 and R2 have the meanings mentioned in relation to formula IIB,
with a suitable reducing agent to afford a compound of formula IIB,
(ii) optionally resolving the racemic mixture, if any, and
(iii) if desired, adding an organic or inorganic acid to a compound of formula IIB to yield the corresponding salt.
13. A process according to claim 11, wherein step (i) is performed by catalytic hydrogenation, or with a suitable reducing agent such as sodium or lithium boron hydride.
14. A pharmaceutical composition containing a therapeutically or a diagnostically effective amount of a compound according to claims 10 and 11, together with one or more pharmaceuticlly acceptable excipients.
EP90200938A 1989-04-20 1990-04-17 Catecholamine esters Expired - Lifetime EP0393782B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2020889 1989-04-20
IT8920208A IT1229846B (en) 1989-04-20 1989-04-20 ESTERS OF CATECOLAMINS.

Publications (3)

Publication Number Publication Date
EP0393782A2 true EP0393782A2 (en) 1990-10-24
EP0393782A3 EP0393782A3 (en) 1991-04-24
EP0393782B1 EP0393782B1 (en) 1994-08-03

Family

ID=11164777

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90200938A Expired - Lifetime EP0393782B1 (en) 1989-04-20 1990-04-17 Catecholamine esters

Country Status (8)

Country Link
US (1) US5144059A (en)
EP (1) EP0393782B1 (en)
JP (1) JPH02292242A (en)
AT (1) ATE109454T1 (en)
CA (1) CA2014972A1 (en)
DE (1) DE69011174T2 (en)
ES (1) ES2060926T3 (en)
IT (1) IT1229846B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509598A1 (en) * 1991-04-19 1992-10-21 ZAMBON GROUP S.p.A. Use of ibopamine for the manufacture of a pharmaceutical composition for the treatment of glaucomatous optic neuropathy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2117954A1 (en) * 1970-12-09 1972-07-28 Aldrich Chem Co Inc
US4035405A (en) * 1976-07-09 1977-07-12 Interx Research Corporation Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives
GB2123826A (en) * 1982-07-22 1984-02-08 Simes Esters of epinine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO129903B (en) * 1969-04-01 1974-06-10 Sterling Drug Inc
US4138581A (en) * 1969-04-01 1979-02-06 Sterling Drugs Inc. 3(Hydroxy or hydroxymethyl)-4(hydroxy)-α-(aminomethyl)benzyl alcohols

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2117954A1 (en) * 1970-12-09 1972-07-28 Aldrich Chem Co Inc
US4035405A (en) * 1976-07-09 1977-07-12 Interx Research Corporation Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives
GB2123826A (en) * 1982-07-22 1984-02-08 Simes Esters of epinine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARZNEIMITTEL FORSCHUNG/DRUG RESEARCH, vol. 36, February 1986, pages 291-303; C. CASAGRANDE et al.: "Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines - Synthesis of ibopamine metabolites" *
CHEMICAL ABSTRACTS, vol. 100, no. 13, 26 March 1984, page 13, abstract no. 96090m, Columbus, Ohio, US; M.A. REDELL et al.: "The role of esterase activity in the ocular disposition of dipivalyl epinephrine in rabbits", & INT. J. PHARM. 1983, vol. 17, no. 2-3, pages 299 - 312 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509598A1 (en) * 1991-04-19 1992-10-21 ZAMBON GROUP S.p.A. Use of ibopamine for the manufacture of a pharmaceutical composition for the treatment of glaucomatous optic neuropathy
US5227404A (en) * 1991-04-19 1993-07-13 Zambon Group S.P.A. Pharmaceutical composition for the treatment of glaucomatous optic neuropathy

Also Published As

Publication number Publication date
ATE109454T1 (en) 1994-08-15
IT1229846B (en) 1991-09-13
EP0393782A3 (en) 1991-04-24
IT8920208A0 (en) 1989-04-20
JPH02292242A (en) 1990-12-03
CA2014972A1 (en) 1990-10-20
EP0393782B1 (en) 1994-08-03
DE69011174D1 (en) 1994-09-08
DE69011174T2 (en) 1995-04-06
ES2060926T3 (en) 1994-12-01
US5144059A (en) 1992-09-01

Similar Documents

Publication Publication Date Title
EP3046906B1 (en) Ror gamma modulators
KR101952457B1 (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
JPH09505596A (en) Heterocyclic esters of rapamycin and pharmaceutical compositions containing them
IE54347B1 (en) Ester and amide derivatives of 13, 14-dihenydro-prostaglandins
RU2195453C2 (en) Cyanoguanidines, methods of their synthesis and pharmaceutical preparation based on thereof
JP2021533152A (en) Nitric oxide-releasing phosphodiesterase type 5 inhibitor
EA030634B1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
EP1539724B1 (en) Amino benzothiazole compounds with nos inhibitory activity
AU2022201182B2 (en) Compositions and Methods for the Treatment of Fungal Infections
JP2020520949A (en) Compositions and methods of preparing and using mitochondrial uncouplers
EP1439164B1 (en) Novel phenylethanolamine compounds having beta2-acceptor excitatory function and their preparation method
EP0393782B1 (en) Catecholamine esters
JP2650739B2 (en) Split aminopyrrolidine neuroprotective agent
US20180118661A1 (en) Compounds and methods for the treatment of neurodegenerative diseases
CA3115162A1 (en) Compositions and methods for the treatment of parkinson's disease
JP7118449B2 (en) Compositions and methods for the treatment of gastrointestinal polyps
US4897423A (en) Dinitrobenzenesulfonamides
KR20230015944A (en) Compounds used as RET kinase inhibitors and uses thereof
EP1940794A2 (en) Quinoline derivatives and use as antitumor agents
EP0765322B1 (en) Indole derivatives as prodrugs of 5-ht1-like receptor agonists
FR2662691A1 (en) DICHLOROANILINE DERIVATIVE.
US11980618B2 (en) Nitric oxide releasing phosphodiesterase type 5 inhibitor
US10633339B2 (en) Tricyclic sulfone compound as a ROR gamma modulator
FI114155B (en) Indole derivatives for the treatment of migraine
EP1534668B1 (en) Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19910906

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ZAMBON GROUP S.P.A.

17Q First examination report despatched

Effective date: 19930416

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Effective date: 19940803

Ref country code: AT

Effective date: 19940803

REF Corresponds to:

Ref document number: 109454

Country of ref document: AT

Date of ref document: 19940815

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69011174

Country of ref document: DE

Date of ref document: 19940908

ITF It: translation for a ep patent filed

Owner name: MARCHI & MITTLER S.R.L.

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2060926

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
EAL Se: european patent in force in sweden

Ref document number: 90200938.0

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3013850

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19950430

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19980309

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19980313

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990430

EUG Se: european patent has lapsed

Ref document number: 90200938.0

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20000315

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20000316

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20000323

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20000327

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20000428

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20000502

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20000630

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20010430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010516

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010516

BERE Be: lapsed

Owner name: ZAMBON GROUP S.P.A.

Effective date: 20010430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20010417

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20011101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050417